

CUMULATIVE INDEX: VOLUME 11

SUBJECT INDEX

Abdominal circumference, 144–148
 Abdominal pregnancy, 350–352
 Abortion, spontaneous, 386–397
 Acetylcholinesterase band, 149–152
 Acid-base balance, 9–13, 71
 Adrenal gland, fetal hemorrhage, 302–304
 Adrenergic blockade, neonatal, 91–93
 Age
 endometritis, 24–26
 gestational, and risk of death, 267–272
 small for gestation, 344–347
 Agenesis
 of diaphragm, 340–343
 renal, 184–186
 Alpha-fetoprotein, 149–152
 chorioangioma and, 245–248
 during pregnancy and in neonate, 279–281
 in prenatal diagnosis, 286–287
 American Academy of Pediatrics, annual meeting, abstracts, 168–177
 Amino acids, excitatory, 169
 Amniotic fluid, acetylcholinesterase band, 149–152
 Amniotic fluid index, predictor of latency after premature rupture of membranes, 249–252
 Anemia, 9–13, 71
 Antibiotic treatment, 40–41
 Antiphospholipid syndrome, 1–3
 Aplastic cutis congenita, 149–152
 Asphyxia
 and infant mortality, 290–294
 risk of, 377–381
 Atresia
 esophageal, 123–128
 pyloric, 286–287
 Bandl's ring, 65–66
 Biopsy, prenatal, 160–162
 Birthweight
 carbon dioxide and, 237–241
 low, 297–301
 macrosomic, 51–56, 260–262
 race and, low, 169–170
 risk for cerebral palsy, low, 377–381
 and risk of death, 267–272

Bleeding
 gastrointestinal, and hemophilia B, 192–193
 third trimester, effect on infant, 85–90, 167
 Blood flow
 fetal, 337–339
 in superior mesenteric artery, 176
 uterine, 313–316, 337–339
 Blood pressure
 insulin and, 369–373
 steroids and, 171
 Bradycardia, congenital, 353–355
 Brain, temperature of, 137–143
 Breach presentation, 348–349
 Bronchial obstruction, for emphysema of infant, 433–435
 Bronchopulmonary dysplasia, 172
 Caffeine, cardiovascular effects of, 132–136
 Calcification, of fetal myocardium, 179–183
 Carbamoyl phosphate synthetase deficiency, 160–162
 Carbon dioxide, transcutaneous levels in low birthweight infants, 237–241
 Cardiac transplantation, pregnancy and, 217–219
 Cardiovascular problems, effect of caffeine, 132–136
 Catheterization
 umbilical arterial, 94–99, 176
 umbilical venous, 67–70
 Cerebellum, transverse diameter, 144–148
 Cerebral infarction, in neonates, 119–122
 Cerebral palsy, risk factors for, 377–381
 Cervical ripening
 hemodynamic effects of, 337–339
 prostaglandin E₂, 309–312, 337–339, 436–439
 Cesarean section
 age and, 24–26
 for fetal entrapment, 348–349
 for failed vaginal birth, 65–66
 preeclampsia and, 288–289
 vaginal delivery after, 309–312
 Chorioamnionitis, 205–207

Chorioangioma, maternal alpha-fetoprotein levels and, 245–248
 Circulation, ovine uteroplacental, 172
 Clinic staff, attitude toward patients, 362–366
 Coagulation screening, of premature infants, 27–29
 Cocaine use, 179–183, 340–343
 Congenital diseases
 absence of diaphragm, 340–343
 bradycardia, 353–355
 goiter, 21–23
 heart, 334–336
 hernia, 176–177
 hyperinsulinism, 113–115
 malformations, 123–128
 Corticosteroids, 163–166, 226–230, 423–426
 in premature infants, 171
 Corticotropin test, 175
 Cysticercosis, during pregnancy, 409–411
 Cysts, placental, 14–18

Death
 fetal, 267–272
 See also Mortality
 Developmental outcome, prediction of, 85–90, 167
 Dexamethasone, effect on pulmonary hypoplasia, in rats, 226–230
 Diabetes
 erythropoietin levels and, 427–429
 insulin-induced hypoglycemia, 231–236
 insulin and blood pressure, 369–373
 macrosomic fetus and, 51–56
 maternal ketoacidosis, 430–432
 nonobese mouse, 51–56
 Diagnosis, prenatal, 160–162
 Diaphragm, absence of, 340–343
 herniation of, 176–177, 412–415
 DNA, of placenta, 14–18
 Dobutamine, for hypotension, 169
 Dopamine, for hypotension, 169
 Doppler flow pattern
 of inferior vena cava, 255–259
 See also Ultrasonography

Echocardiography, for fetal heart disease, 334–336

CUMULATIVE INDEX: VOLUME 11

SUBJECT INDEX

Abdominal circumference, 144–148
 Abdominal pregnancy, 350–352
 Abortion, spontaneous, 386–397
 Acetylcholinesterase band, 149–152
 Acid-base balance, 9–13, 71
 Adrenal gland, fetal hemorrhage, 302–304
 Adrenergic blockade, neonatal, 91–93
 Age
 endometritis, 24–26
 gestational, and risk of death, 267–272
 small for gestation, 344–347
 Agenesis
 of diaphragm, 340–343
 renal, 184–186
 Alpha-fetoprotein, 149–152
 chorioangioma and, 245–248
 during pregnancy and in neonate, 279–281
 in prenatal diagnosis, 286–287
 American Academy of Pediatrics, annual meeting, abstracts, 168–177
 Amino acids, excitatory, 169
 Amniotic fluid, acetylcholinesterase band, 149–152
 Amniotic fluid index, predictor of latency after premature rupture of membranes, 249–252
 Anemia, 9–13, 71
 Antibiotic treatment, 40–41
 Antiphospholipid syndrome, 1–3
 Aplastic cutis congenita, 149–152
 Asphyxia
 and infant mortality, 290–294
 risk of, 377–381
 Atresia
 esophageal, 123–128
 pyloric, 286–287
 Bandl's ring, 65–66
 Biopsy, prenatal, 160–162
 Birthweight
 carbon dioxide and, 237–241
 low, 297–301
 macrosomic, 51–56, 260–262
 race and, low, 169–170
 risk for cerebral palsy, low, 377–381
 and risk of death, 267–272

Bleeding
 gastrointestinal, and hemophilia B, 192–193
 third trimester, effect on infant, 85–90, 167
 Blood flow
 fetal, 337–339
 in superior mesenteric artery, 176
 uterine, 313–316, 337–339
 Blood pressure
 insulin and, 369–373
 steroids and, 171
 Bradycardia, congenital, 353–355
 Brain, temperature of, 137–143
 Breach presentation, 348–349
 Bronchial obstruction, for emphysema of infant, 433–435
 Bronchopulmonary dysplasia, 172
 Caffeine, cardiovascular effects of, 132–136
 Calcification, of fetal myocardium, 179–183
 Carbamoyl phosphate synthetase deficiency, 160–162
 Carbon dioxide, transcutaneous levels in low birthweight infants, 237–241
 Cardiac transplantation, pregnancy and, 217–219
 Cardiovascular problems, effect of caffeine, 132–136
 Catheterization
 umbilical arterial, 94–99, 176
 umbilical venous, 67–70
 Cerebellum, transverse diameter, 144–148
 Cerebral infarction, in neonates, 119–122
 Cerebral palsy, risk factors for, 377–381
 Cervical ripening
 hemodynamic effects of, 337–339
 prostaglandin E₂, 309–312, 337–339, 436–439
 Cesarean section
 age and, 24–26
 for fetal entrapment, 348–349
 for failed vaginal birth, 65–66
 preeclampsia and, 288–289
 vaginal delivery after, 309–312
 Chorioamnionitis, 205–207

Chorioangioma, maternal alpha-fetoprotein levels and, 245–248
 Circulation, ovine uteroplacental, 172
 Clinic staff, attitude toward patients, 362–366
 Coagulation screening, of premature infants, 27–29
 Cocaine use, 179–183, 340–343
 Congenital diseases
 absence of diaphragm, 340–343
 bradycardia, 353–355
 goiter, 21–23
 heart, 334–336
 hernia, 176–177
 hyperinsulinism, 113–115
 malformations, 123–128
 Corticosteroids, 163–166, 226–230, 423–426
 in premature infants, 171
 Corticotropin test, 175
 Cysticercosis, during pregnancy, 409–411
 Cysts, placental, 14–18

Death
 fetal, 267–272
 See also Mortality
 Developmental outcome, prediction of, 85–90, 167
 Dexamethasone, effect on pulmonary hypoplasia, in rats, 226–230
 Diabetes
 erythropoietin levels and, 427–429
 insulin-induced hypoglycemia, 231–236
 insulin and blood pressure, 369–373
 macrosomic fetus and, 51–56
 maternal ketoacidosis, 430–432
 nonobese mouse, 51–56
 Diagnosis, prenatal, 160–162
 Diaphragm, absence of, 340–343
 herniation of, 176–177, 412–415
 DNA, of placenta, 14–18
 Dobutamine, for hypotension, 169
 Dopamine, for hypotension, 169
 Doppler flow pattern
 of inferior vena cava, 255–259
 See also Ultrasonography
 Echocardiography, for fetal heart disease, 334–336

Eclampsia, postpartum, 288–289
 Electroconvulsive therapy, during pregnancy, 116–118
 Emphysema, of infant, 433–435
 Endometritis, age and, 24–26
 Enterocolitis, necrotizing, 30–32
 Entrapment of fetus, 348–349
Epidermolysis bullosa, 286–287
 Erythrocytes, nucleated, and congenital hyperinsulinism, 113–115
 Erythropoietin serum levels during labor, 427–429
Escherichia coli, 205–207
 Esophagus, atresia of, 123–128
 Exercise, fetal response to maternal, 263–266
 Exomphalos, 14–18
 Extracorporeal membrane oxygenation hernia and, 176–177
 for respiratory failure, 174
 Eye splash, risk in obstetrics, 359–361

Feeding
 enteral, 176
 formula, 173
 Femur length, 144–148
 Fentanyl, 173
 Fern test, 46–50
 Fetus
 cardiac effects of tocolysis, 109–112
 cardiac response to testing, 73–79
 distress, 194–198, 302–304, 430–432
 effect of electroconvulsive therapy on, 116–118
 effect of labetalol on, 91–93
 effect of magnesium sulfate on, 401–403
 effect of maternal exercise on, 263–266
 entrapment of, 348–349
 heart rate and distress, 194–198
 hemorrhage, 253–254, 302–304
 intracranial teratoma, 420–422
 liver length, 344–347
 motor response to testing, 73–79
 nalbuphine effect on, 367–368
 nonimmune hydrops, 253–254, 317–319, 439–440
 risk of prednisone on, 423–426
 Foramen ovale, premature closure, 439–440
 Formula feeding, and growth, 171–172
 Fracture, clavicle of neonate, 331–333
 Fructosamine, maternal, 4–8

Gastrointestinal bleeding, 192–193
 Genetic disorders
 mosaicism 45,X/46,XY, 184–186
 neonatal mortality from, 100–103
 trisomy 9, 80–81
 trisomy 21, 19–20
 Gentamicin, for pyelonephritis, 40–41
 Gestational dating, 404–408
 Glucose-6-phosphate dehydrogenase deficiency, 174
 Goiter, congenital, 21–23
 Growth
 formula feeding and, 171–172
 model of fetal organs, 320–325
 retardation, 144–148
 small for gestational age, 344–347

Habituation testing, 73–79
Haemophilus influenzae type b, 170–171
 Head circumference, 144–148

Heart
 congenital disease, 334–336
 fetal rate, and fetal distress, 194–198
 fetal rate response to vibroacoustic stimulation, 273–278
 twin fetal rates, 208–212

Hemoglobin
 concentration, 9–13
 glycosylated, 260–262
 Hemoglobinopathy, sickle cell disease and, 187–191

Hemophilia B, gastrointestinal bleeding and, 192–193

Hemorrhage
 fetal adrenal gland, 302–304
 fetal intracranial, 253–254

Hernia, diaphragmatic, 104–108, 129–131, 176–177, 340–343, 412–415

Human immunodeficiency virus, transmission of, 326–330

Hydrocephalus, 253–254

Hydrops, nonimmune, 253–254, 317–319, 439–440

Hygroma, cystic, 19–20

Hyperbilirubinemia
 glucose-6-phosphate dehydrogenase deficiency, 174
 skin color and, 223–225

Hyperglycemia
 maternal, 51–56
 in newborn, 4–8

Hyperinsulinism
 congenital, 113–115
 hypoglycemia and, 374–376

Hypertension
 neonatal, 302–304
 in pregnancy, 313–316

Hypoglycemia,
 amino acids release, 169
 hyperinsulinism and, 374–376
 insulin-induced, 231–236

Hypoplasia
 pulmonary, of fetus, 104–108
 of rat 226–230

Hypotension, drugs for, 169

Hypothyroidism, of newborn, 30–32

Hysterectomy, eclampsia and, 288–289

Immunoglobulin preparations, 170

Indomethacin
 intrauterine treatment with, 295–296
 for patent ductus arteriosus, 220–222

Infants
 anion gap in mechanical ventilation, 213–216
 coagulation screening, 27–29
 effect of sound on sick, 173–174
 emphysema, 433–435
 hypotension in, 169
 low birthweight, 85–90, 167
 response to *Haemophilus* vaccine, 170–171
 risk of thrombocytopenia, 423–426
 sepsis in, 176
 transcutaneous carbon dioxide and low birthweight, 237–241

See also Neonates

Infections
 antibiotic treatment of, 40–41
 cysticercosis during pregnancy, 409–411
 parvovirus B19, 398–400
 in rabbits, 173
 response of neonate to, 282–285

Risks in obstetrics, 359–361

Insulin
 and blood pressure, 369–373
 hyperinsulinism, 374–376
 hypoglycemia, 231–236

Interleukins, in neonate, 176, 282–285

Intestine, perforation of small, 295–296

Intracranial hemorrhage, of fetus, 253–254

Ischemia, upper limb, 119–122

Isoimmunization, maternal, 374–376

Ketoacidosis, maternal, 430–432

Kidney, nonfunctioning in neonate, 302–303

Labetalol, effect on fetus, 91–93

Labor
 erythropoietin levels, preterm, 427–429
 induction with prostaglandin E₂, 309–312, 337–339, 436–438
 preterm, 297–298

Leiomyoma, uterine, 356–358

Leukocytes, and natural surfactant, 33–36

Limb ischemia, upper, 119–122

Liver, fetal length, 344–347

Lung model, 177

Macrosomia
 cause of, 51–56
 fetal and birthweight, 260–262
 prediction of, 144–148

Magnesium sulfate
 effect on fetus, 401–403
 in preeclampsia, 153–156

Malformations, congenital, 123–128

Membranes, ruptured, 46–50

Metabolism, inborn error of, 160–162

Miscarriage, recurrent, 386–397

Möbius sequence, 157–159

Modeling, of fetal organ growth, 320–325

Monitoring, fetus with bradycardia, 353–355

Morbidity, of fetus from third trimester bleeding, 85–90, 167

Mortality
 of fetus from parvovirus B19, 398–400
 genetic disorders and, 100–103
 of infant, 290–294

Mosaicism, 45,X/46,XY, 184–185

Mouse, nonobese diabetes, 51–56

Myocardium
 fetal calcification, 179–183
 infarction, postpartum, 1–3

Nalbuphine, effect on fetus, 367–368

Neonates
 alpha-fetoprotein in, 279–281
 brain temperature of, 137–143
 cerebral infarction, 119–122
 clavicle fracture, 331–333
 genetic disorders, 100–103
 hemophilia B, 192–193
 hyperinsulinism and hypoglycemia, 374–376
 hypertension, 302–304
 hypothyroidism, 30–32
 interleukins, 176, 282–285
 interventions by pediatricians, 175
 low birthweight, 163–166
 nonfunctioning kidney, 302–304
 pulmonary blood flow after surfactant, 382–385

response to infection, 282–285
 steroids, 177
See also Infants
Neurodevelopmental impairment of fetus, from bleeding in third trimester, 85–90, 167
Neutrophil motility, 163–166
Newborn. *See Infants, Neonates*
Nitric oxide, 168–169
Nitric oxide synthase, 168

Obstetric procedures, risks of, 359–361
Oligohydramnios, 104–108
 in rat fetus, 226–230
Oliguria, after indometacin treatment, 220–222
Ovine uteroplacental circulation, 172
Oxygenation of fetus, 9–13, 71

Parvovirus B19, 398–400
Patent ductus arteriosus, treatment of, 220–222
Perinatal care
 complications of catheterization, 67–70, 94–99
Perinatal Pediatrics Program, 168–177
Perirenal air, 63–64
Placenta
 cysts, 14–18
 DNA, 14–18
 pathology of, 326–330
Platelet activating factor, 172
Platelets
 fetal, 42–45
 maternal, 374–376
Pneumoretroperitoneum, 63–64
Pneumothorax, tension, 63–64
Polyhydramnios, midtrimester, 305–308
Predictions
 amniotic fluid index and premature rupture of membranes, 249–252
 early mortality and neurodevelopmental outcome, 85–90, 167
 growth parameters in twin gestation, 199–204
Prednisone, effect on fetus, 423–426
Preeclampsia
 cesarean section and, 288–289
 erythropoietin levels and, 427–429
 phenytoin treatment, 159–156
Pregnancy
 abdominal, 350–352
 alpha-fetoprotein during, 279–281
 dating of, 404–408
 hemoglobinopathy and, 187–191
 hypertension in, 313–316
 induction of labor, 309–312, 436–438
 insulin-induced hypoglycemia in diabetics, 231–236
 intervals between, 169–170
 leiomyomas and, 356–358
 patient reaction to clinic staff, 362–366
 premature rupture of membranes, 249–252, 416–419, 436–438
 recurrent miscarriage, 386–397
 seizures during, 409–411
Premature infants
 coagulation studies of, 27–29
 corticotropin test, 175
 morbidity from third trimester bleeding, 85–90
 risk of cerebral palsy, 377–381
 steroids and blood pressure, 171
Prenatal clinic, staff attitude toward patients, 362–366
Prostaglandin E₂, 309–312, 337–339, 436–438
Pulmonary blood flow, in neonate, 382–385
Pylonephritis, gentamicin for, 40–41
Pyloris, atresia of, 286–287

Race, and risk of death, 267–272
Rat
 injury from nitric oxide, 168–169
 nitric oxide synthase inhibition in, 168
Renal failure, in twin gestation, 242–244
Renal hypoplasia and agenesis, 184–186
Respiratory distress syndrome
 complications of, 433–435
 fentanyl for, 173
 neonatal, 382–385
 surfactant and, 174
 ventilation for, 174–175
Risk factors, maternal, for HIV infection, 326–330
Ritodrine, effect on fetus, 109–112
Rossavik growth model, 320–325
Rupture of membranes, premature
 amniotic fluid index, 249–252
 labor induction after, 436–438
 latency and, 416–419

Sacculation of uterus, 350–352
Scalp smear, fetal, 42–45
Screening
 coagulation, 27–29
 importance of, 174
 for toxoplasmosis, 57–62
Seizures during pregnancy, 409–411
Sepsis
 in infants, 176
 maternal caused by *Escherichia coli*, 205–207
Sickle cell disease, 187–191
Skin color, and hyperbilirubinemia, 223–225
Sound, effect on sick preterm infant, 173–174
Steroids
 antenatal, 171
 inhaled, 177
See also Corticosteroids
Stimulation, vibroacoustic, response to, 273–278, 401–403
Streptococcus, tests for, 177
Stress, thermal, 313–316
Superior mesenteric artery, 176
Surfactant, 174
 effect on leukocytes, 33–36
 effect on pulmonary blood flow, 382–385

Tachycardia, fetal, 367–368
Temperature, of brain, 137–143
Teratoma, fetal intracranial, 420–422
Tests
 corticotropin, 175
 fetal response to, 73–79
 urine antigen, 177
Thrombocytopenia, 374–376
 risk in infants, 423–426

Thyroid gland, 21–23
Thyroxine treatment, 30–32
Tocolysis
 effect on fetus, 109–112
 with indomethacin, 295–296
Toxoplasmosis, congenital, prevention of, 57–62
Transfusion, twin-twin, 317–319
Transplantation, pregnancy after, 217–219
Trauma, neonatal clavicle fracture, 331–333
Triiodothyronine, effect on pulmonary hypoplasia in rats, 226–230
Trisomy 9, ultrasound findings, 80–84
Trisomy 21, 19–20
Tumor necrosis factor, in neonate, 282–285

Twins
 behavior in utero, 208–212
 effect of electroconvulsive therapy on, 116–118
 maternal obstructive renal failure, 242–244
 predicting discordancy, 199–204
 twin-twin transfusion, 317–319

Ultrasonography
 diagnostic, 297–301
Doppler, 21–23, 255–259, 337–339
 growth parameters for predicting discordancy, 199–204
 for Möbius sequence, 157–159
 for pulmonary hypoplasia of fetus, 104–108
 for intracranial teratoma, 420–422
 for trisomy 9, 80–81
 uterine sacculation vs abdominal pregnancy, 350–352
Umbilical artery, catheterization of, 94–99, 176
Umbilical vein
 catheterization of, 67–70
 pressure in inferior vena cava, 155–159
Ureaplasma urealyticum, 173
Urethral valves, in successive generations, 37–39
Urine antigen tests, 177
Uterus
 blood flow in, 313–316
 leiomyomas of, 356–358
 sacculation of, 350–352

Vaccine, for *Haemophilus influenzae*, 170
Vaginal birth, failed, 65–66
Vena cava
 inferior, of fetus, 255–259
 syndrome, 129–131
Ventilation
 anion gap in mechanical, of newborn, 213–216
 oscillatory, for emphysema, 433–435
 in respiratory failure, 174–175
Ventricle, cardiac, growth model of, 320–325
Vibroacoustic stimulation, 273–278, 401–403

Women, nonpregnant, insulin-induced hypoglycemia and, 231–236

Zavanelli maneuver, 348–349

